NCT01998438

Prospective Trial of Tranexamic Acid in Cardiac Surgery

A Randomized Double-blinded Trial to Explore the Optimum Dose of Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 955 (actual)
• Sponsor: Hongwen Ji · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Tranexamic acid, an antifibrinolytic drug, is wildly used in cardiac surgeries to decrease perioperative bleeding and allogenic transfusion. But the optimum dose of tranexamic acid is still unknown. We use three different doses to find which is the optimum dose of tranexamic acid in cardiopulmonary bypass cardiac surgery.

Conditions

• C.Surgical Procedure; Cardiac

Interventions

Type	Name	Description
DRUG	Tranexamic Acid	The loading doses were given in 15 minutes when incision.

Timeline

• Start date: 2012-09-01
• Primary completion: 2014-09-01
• Completion: 2014-09-01
• First posted: 2013-11-28
• Last updated: 2016-02-26
• Results posted: 2016-02-26

Locations

1 site across 1 country: China